Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...

Every fall and winter, the United States sees an uptick in the number of people who fall ill to influenza and other seasonal diseases. This flu season typically stretches from October to ...

Pfizer's RSV vaccine Abrysvo – given to the mother ... Approximately 1% to 3% of children under 12 months of age in the US are hospitalised each year due to RSV, according to figures from ...

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

A new study has found a major drop in respiratory syncytial virus (RSV) related hospitalisations following vaccination ...

RSV infection that is managed via primary care in children under 5 years of age leads to a substantial burden for families, primary care resources, and society.

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

As cold and flu season continues in Vermont, UVMMC is urging families to get their newborns and infants preventatively ...